AgingResearch.NewsJoin free

Privo Technologies

CompanyUnited States

Wikidata

Privo Technologies develops 2 assets, the furthest in phase 2 (PRV111 in early-stage oral cancer). Mostly small molecule acting on DNA damage response, apoptosis and DNA repair; based in the United States.

2
Assets
Furthest stage
Phase 2
2
Trials
0
Signals

Pipeline

2

  • PRV111

    Platinum-based DNA crosslinking agent formulated for transmucosal or intraoperative local delivery.

    Phase 2, Small molecule, DNA damage response, DNA repair, early-stage oral cancer, oral cancer

  • PRV211

    Intraoperative local cisplatin delivery inducing DNA crosslinks and tumor cell death

    Phase 2, Small molecule, DNA damage response, Apoptosis, oral squamous cell carcinoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials2
  • Similar companies6

Intelligence